Publication Date:
1983-01-28
Description:
A commercial alpha-amylase inhibitor with potent inhibitory activity in vitro was used in a randomized double-blind, cross-over clinical trial in six nonobese, healthy adult males. In these subjects, this inhibitor had no effect on the response of blood glucose, insulin, or breath hydrogen to a standardized starch meal. It is concluded that this formulation has no effect on starch digestion in humans.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Carlson, G L -- Li, B U -- Bass, P -- Olsen, W A -- 5P30 AM 26659/AM/NIADDK NIH HHS/ -- AM 13927/AM/NIADDK NIH HHS/ -- AM 21668/AM/NIADDK NIH HHS/ -- New York, N.Y. -- Science. 1983 Jan 28;219(4583):393-5.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/6184780" target="_blank"〉PubMed〈/a〉
Keywords:
Amylases/*antagonists & inhibitors
;
Blood Glucose/metabolism
;
Dietary Carbohydrates/*metabolism
;
Humans
;
Hydrogen/metabolism
;
Insulin/blood
;
alpha-Amylases/*antagonists & inhibitors
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
